Advertisement

Topics

A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis

2019-04-22 14:08:22 | BioPortfolio

Published on BioPortfolio: 2019-04-22T14:08:22-0400

Clinical Trials [1911 Associated Clinical Trials listed on BioPortfolio]

Examination of Efficacy and Safety of Baricitinib in RA Patients

The aim of this study is to examine the efficacy and adverse events in the following 3 groups in rheumatoid arthritis patients: 1. Baricitinib treatment for 12 months 2. Biolog...

Effect of Baricitinib Treatment on Peripheral Bone in RA

Patients with Rheumatoid Arthritis (RA) suffer systemic and peripheral bone loss. In this study we aim to test the efficacy of in-label treatment with Baricitinib on the volumetric bone mi...

Effects of Antirheumatic Treatment on Levels of Survivin in Rheumatoid Arthritis Patients

To validate the utility of survivin as a biomarker of pharmacological response to therapeutic intervention in rheumatoid arthritis patients.

A Study in Moderate to Severe Rheumatoid Arthritis Participants

The purpose of this study is to determine whether baricitinib 4 milligram (mg) once daily (QD) is superior to placebo in the treatment of participants with moderately to severely active Rh...

A Study of P38 Inhibitor (4) Monotherapy in Patients With Active Rheumatoid Arthritis

This 4 arm study will compare the safety and efficacy, with regard to reduction of signs and symptoms, of P38 Inhibitor (4) (50, 150 or 300mg po qd) monotherapy versus methotrexate monothe...

PubMed Articles [4685 Associated PubMed Articles listed on BioPortfolio]

Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment.

Baricitinib is an oral, once-daily selective Janus kinase (JAK1/JAK2) inhibitor for adults with moderately to severely active rheumatoid arthritis (RA). We evaluated baricitinib's safety profile throu...

Citrullinated Inhibitor of DNA Binding 1 is a Novel Autoantigen in Rheumatoid Arthritis.

We explored the intrinsic role of inhibitor of DNA binding 1 (ID1) in rheumatoid arthritis (RA) fibroblast-like synoviocytes (FLS) and investigated whether ID1 is citrullinated and autoantigenic in RA...

Fibromyalgia in patients with rheumatoid arthritis. A 10-year follow-up study, results from the Oslo Rheumatoid Arthritis Register.

To examine cross-sectional and longitudinal relationships between fibromyalgia (FM) and rheumatoid arthritis (RA) disease activity.

DNA methyltransferase inhibitor 5'-azacytidine ameliorates autoimmune arthritis in mice.

Disease-associated, differentially hypermethylated regions have been reported in rheumatoid arthritis (RA) but no DNA methyltransferase inhibitors have been evaluated in either RA or in any animal mod...

Tryptophan metabolism in rheumatoid arthritis is associated with rheumatoid factor and predicts joint pathology evaluated by the Rheumatoid Arthritis MRI Score (RAMRIS).

Tryptophan and its metabolites have been suggested to play a role in inflammatory processes. However, studies in rheumatoid arthritis (RA) are scarce, which prompted us to investigate two cohorts of R...

Medical and Biotech [MESH] Definitions

Arthritis in children, with onset before 16 years of age. The terms juvenile rheumatoid arthritis (JRA) and juvenile idiopathic arthritis (JIA) refer to classification systems for chronic arthritis in children. Only one subtype of juvenile arthritis (polyarticular-onset, rheumatoid factor-positive) clinically resembles adult rheumatoid arthritis and is considered its childhood equivalent.

Rheumatoid arthritis of children occurring in three major subtypes defined by the symptoms present during the first six months following onset: systemic-onset (Still's Disease, Juvenile-Onset), polyarticular-onset, and pauciarticular-onset. Adult-onset cases of Still's disease (STILL'S DISEASE, ADULT-ONSET) are also known. Only one subtype of juvenile rheumatoid arthritis (polyarticular-onset, rheumatoid factor-positive) clinically resembles adult rheumatoid arthritis and is considered its childhood equivalent.

A pyrazole derivative and selective CYCLOOXYGENASE 2 INHIBITOR that is used to treat symptoms associated with RHEUMATOID ARTHRITIS; OSTEOARTHRITIS and JUVENILE ARTHRITIS, as well as the management of ACUTE PAIN.

A variable mixture of the mono- and disodium salts of gold thiomalic acid used mainly for its anti-inflammatory action in the treatment of rheumatoid arthritis. It is most effective in active progressive rheumatoid arthritis and of little or no value in the presence of extensive deformities or in the treatment of other forms of arthritis.

Systemic-onset rheumatoid arthritis in adults. It differs from classical rheumatoid arthritis in that it is more often marked by acute febrile onset, and generalized lymphadenopathy and hepatosplenomegaly are more prominent.

More From BioPortfolio on "A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis"

Advertisement
Quick Search
Advertisement
Advertisement

 

Searches Linking to this Trial